3 April 2023. Medherant (Coventry, UK) announces that it has raised £2.9m of new funding from investors in a financing round led by Mercia Asset Management.
5th April 2023
4th May 2020
Cambridge & Coventry, UK – 5 May 2020 – Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (Medherant) are pleased to announce that they have signed an agreement to develop and commercialize mult
25th June 2019
Coventry, UK, 25th June 2019 / Medherant Limited (“Medherant”), the clinical-stage company developing innovative products for pain and CNS diseases using a u
21st May 2019
Coventry, UK, 21st May 2019 / Medherant Limited (“Medherant”), the clinical-stage developer of innovative transdermal delivery products for pain and CNS dise
5th November 2018
Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI Patch®.
3rd October 2018
Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medicines Manufacturing Grant by Innovate UK.
11th December 2017
Medherant, a leader in next-generation transdermal drug delivery, has raised £3.8 million in its latest funding round. The fundraising was led by majority shareholder Mercia Technologies PLC, with the balance coming from other existing shareholders as well as new private investors. This latest investment will support the company as it progresses its ibuprofen TEPI Patch® into clinical development in early 2018.
17th November 2017
Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwickshire which have achieved success for themselves, their staff and their customers.
27th September 2017
Medherant, a leader in next-generation transdermal drug delivery, has signed an agreement with a Japanese transdermal patch company (“the company”), one of the world’s largest patch developers and manufacturers, to evaluate the potential of its TEPI Patch®
26th June 2017
Medherant Ltd, a University of Warwick spin-out company developing a next-generation transdermal drug delivery patch technology, is pleased to announce the appointment of two new senior executives, Sally Waterman and Angus Hone. These appointments mark a significant expansion of the Company’s management team to support the business as it moves into clinical development and commercialisation of its ibuprofen TEPI Patch®.